Crispr Therapeutics (NASDAQ:CRSP) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other research firms have also recently commented on CRSP. Chardan Capital restated a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, August 14th. Barclays restated a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a research note on Friday, September 8th. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Finally, SunTrust Banks restated a “hold” rating and set a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. Crispr Therapeutics currently has a consensus rating of “Hold” and an average target price of $22.38.

Crispr Therapeutics (CRSP) traded up $0.13 during midday trading on Friday, reaching $19.12. 324,661 shares of the company’s stock were exchanged, compared to its average volume of 260,319. Crispr Therapeutics has a 12 month low of $11.63 and a 12 month high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The firm had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. During the same quarter in the previous year, the business posted ($2.77) EPS. Crispr Therapeutics’s revenue was up 54.2% on a year-over-year basis. equities analysts forecast that Crispr Therapeutics will post -2.46 earnings per share for the current year.

In other news, CEO Rodger Novak sold 18,470 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $20.76, for a total transaction of $383,437.20. Following the sale, the chief executive officer now owns 1,148,007 shares in the company, valued at $23,832,625.32. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Thomas Woiwode sold 1,700 shares of Crispr Therapeutics stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the sale, the director now owns 8,218 shares in the company, valued at approximately $166,085.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,370 shares of company stock worth $421,842. 39.98% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its position in shares of Crispr Therapeutics by 459.7% during the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares during the last quarter. Capital Investment Advisory Services LLC bought a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $193,000. Ark Investment Management LLC bought a new stake in shares of Crispr Therapeutics during the second quarter valued at approximately $206,000. Moloney Securities Asset Management LLC bought a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $235,000. Finally, Vanguard Group Inc. bought a new stake in shares of Crispr Therapeutics during the second quarter valued at approximately $273,000. Hedge funds and other institutional investors own 24.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/12/02/bidaskclub-downgrades-crispr-therapeutics-crsp-to-hold.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.